Skip Navigation
Search Menu
Find an Expert

 


Subroto B. Chatterjee, M.S., M.Sc., Ph.D.

Photo of Dr. Subroto B. Chatterjee, M.S., M.Sc., Ph.D.

Director, Sphingolipid Signaling and Vascular Biology Laboratory

Professor of Pediatrics

Research Interests: Drug discovery and biotechnology; Lipid and vascular biology translational research

Contact for Research Inquiries

Division of Pediatric Cardiology
1383 Blalock Building
Johns Hopkins Hospital
Baltimore, MD 21287 map

Email me

Background

Dr. Subroto Chatterjee is a professor of pediatrics at the Johns Hopkins University School of Medicine. He is an internationally recognized expert in glycolipids, atherosclerosis and vascular biology. His research team recently discovered how to halt the development of atherosclerotic heart disease in animals.

Dr. Chatterjee serves as the director of the Sphingolipid Signaling and Vascular Biology Laboratory.

His team is currently studying how glycosphinglipids in vascular cells regulate the onset of atherosclerosis and hypercholesterolemia.

Dr. Chatterjee received his undergraduate degree in chemistry from Lucknow University in India. He earned his M.Sc. in biochemistry from Lucknow University, his M.S. in biochemistry from Dalhousie University in Canada, and his Ph.D. in biochemistry from the University of Toronto. He completed a post-doctoral fellowship in biochemistry at Michigan State University. Dr. Chatterjee joined the Johns Hopkins faculty in 1975.

Prior to joining Johns Hopkins, Dr. Chatterjee was a research associate at Michigan State University. He served as the director of the Atherosclerosis and Vascular Biology Program at Johns Hopkins Singapore for five years.

In addition to his research activities, Dr. Chatterjee teaches M.D. and Ph.D. candidates in the Cell and Molecular Medicine graduate program. He has published more than 250 peer-reviewed papers, review articles, and book chapters in the areas of glycosphingolipids, glycosyltransferases, atherosclerosis , lipoproteins and vascular biology. He has approximately 75 U.S. and worldwide patents for his discoveries and inventions, and has founded three biotechnology companies.

Dr. Chatterjee serves on the scientific advisory board and as a thought leader to Merck. He is a member of several professional organizations, including the Federation of the American Society of Biological Chemists and the American Society for the Advancement of Science. Dr. Chatterjee has received numerous national and international awards for his service to the American heart Association. In addition, he received the Distinguished Scientist award from Gov. Parris Glendening of Maryland, the Mizutani Award and the Distinguished Medical Research Scientist Award from the Ranbaxy Science Foundation in 2004.

...read more

Titles

  • Director, Sphingolipid Signaling and Vascular Biology Laboratory
  • Professor of Pediatrics
  • Professor of Medicine

Departments / Divisions

Education

Degrees

  • M.Sc., Lucknow University (India) (1966)
  • M.S., Dalhousie University (Canada) (1968)
  • Ph.D., University of Toronto (Canada) (1972)

Additional Training

Michigan State University, East Lansing, MI, 1974, Biochemistry

Research & Publications

Research Summary

Dr. Chatterjee studies lipids and vascular biology, with a particular focus on the treatment of atherosclerotic heart disease. He is actively engaged in translational research in US and with his collaborators in Singapore.

In his most recent research, Dr. Chatterjee and his team of researchers halted the development of atherosclerotic heart disease in animals by blocking the activity of a sugar-and-fat molecule residing in the membranes of cells.

Lab

Dr. Chatterjee and his team examine the critical roles of glycosphinglipids (GSLs) within the vascular cells in regulating the onset of atherosclerosis and hypercholesterolemia, which play an important role in the early stages of heart attacks and heart disease. In this project, they identify an attractive therapeutic intervention that could ameliorate atherogenesis and cardiovascular disease (CVD) by targeting angiogenesis and cell proliferation regulated by glycosphingolipids. In collaboration with other projects and core laboratory facilities, they will develop new drugs aimed at ameliorating glycosphingolipid synthesis and atherogenesis accompanied by changes in the proteomics of glycosyltransferases. These studies may not only lay the foundation for the use of such agents to treat human CVD but also determine whether glycosphingolipid glycosyltransferases could serve as important biomarkers of the progression and severity of this disease

Selected Publications

View all on Pubmed

Chatterjee S, Mishra S, Suzuki SK. "New vis-tas in lactosylceramide research." Adv Exp Med Biol. 2015;842:127-38. doi: 10.1007/978-3-319-11280-0_8.

Chatterjee S, Bedja D, Mishra S, Amuzie C, Avolio A, Kass DA, Berkowitz D, Renehan M. "Inhibition of glycosphingolipid synthesis ameliorates atherosclerosis and arterial stiffness in apolipoprotein E-/- mice and rabbits fed a high-fat and -cholesterol diet." Circulation. 2014 Jun 10;129(23):2403-13. doi: 10.1161/CIRCULATIONAHA.113.007559. Epub 2014 Apr 7.

Mishra S, Chatterjee S. "Lactosylceramide promotes hypertrophy through ROS generation and activation of ERK1/2 in cardiomyocytes." Glycobiology. 2014 Jun;24(6):518-31. doi: 10.1093/glycob/cwu020. Epub 2014 Mar 21.

Chatterjee S, Alsaeedi N, Hou J, Bandaru VV, Wu L, Halushka MK, Pili R, Ndikuyeze G, Haughey NJ. "Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model." PLoS One. 2013 May 9;8(5):e63726. doi: 10.1371/journal.pone.0063726. Print 2013.

McNeal CJ, Chatterjee S, Hou J, Worthy LS, Larner CD, Macfarlane RD, Alaupovic P, Brocia RW. "Human HDL containing a novel apoC-I isoform induces smooth muscle cell apoptosis." Cardiovasc Res. 2013 Apr 1;98(1):83-93. doi: 10.1093/cvr/cvt014. Epub 2013 Jan 25.

Academic Affiliations & Courses

Graduate Program Affiliation

Cellular and Molecular Medicine

Activities & Honors

Honors

  • Distinguished Medical Research Scientist Award, Ranbaxy Science Foundation, 2004
  • National Society for Outstanding Professionals, 2003
  • Monobishu Foundation International Award, 1997
  • Research Grant, Mizutani Foundation of Japan, 1995
  • Stanley Foundation Award, 1995 - 1997
  • Distinguished Scientist in the State of Maryland Citation Award, 1995
  • Fellowship (recognition for contributions to AHA science in the state of Maryland), American Heart Association, 1990
  • Tokten Award, United Nations Development Program, 1992
  • Outstanding Paper (Atherosclerosis), Atherosclerosis Digest, 1992
  • Allstar Award, American Heart Association, 1990

Memberships

  • American Heart Association (Fellow, 2005
    Council on Atherosclerosis)
  • American Society for the Advancement of Science
  • American Society of Complex Carbohydrates
  • Federation of the American Society of Biological Chemists
  • International Conference on the Biochemistry of Lipids

Professional Activities

  • Member, Henrietta Lacks Memorial Fellowship Committee, Baltimore, MD, 2010
  • Member, Scientific Advisory Board, Merck, Kenilworth, NJ
Is this you? Edit Profile